|
Dec 6
|
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Dec 1
|
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
|
Aug 10
|
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|
|
Aug 8
|
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|
|
Apr 27
|
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
|
|
Apr 24
|
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
|